Transpharmation

Executive Summary

Transpharmation is a London-based preclinical CRO specializing in translational neuroscience, leveraging its unique access to the world's largest laboratory beagle colony to model naturally occurring, age-related diseases. Founded in 2009, the company provides robust animal models and drug development services tailored to advance client programs from discovery to clinic. Its differentiated position in the CRO market lies in the ability to study spontaneous disease progression in beagles, offering more translationally relevant data compared to induced models. This niche capability is particularly valuable for neurodegenerative and age-related conditions, where traditional rodent models often fall short. With a focus on high-quality, reproducible data, Transpharmation serves a growing demand from pharma and biotech partners seeking preclinical validation with higher predictive value.

Upcoming Catalysts (preview)

• Q3 2026New strategic partnership with a top-20 pharma company for neurodegenerative disease models40% success
• Q2 2026Publication of key beagle model validation data for Alzheimer's disease in a peer-reviewed journal50% success
• Q4 2026Expansion into metabolic and cardiovascular disease modeling using the beagle colony30% success